ROSEN, A LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 05, 2025 6:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), ...

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 29, 2025 [3]. - The lawsuit alleges that DexCom made false statements regarding the reliability and safety of its G6 and G7 continuous glucose monitoring systems, which were not authorized by the FDA [5]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom's design changes to the G6 and G7 systems rendered them less reliable, posing health risks to users [5]. - It is alleged that the company overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues related to the devices [5]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these misleading statements [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].

Financial Data and Key Metrics Changes - Software revenue in Q3 was $35.2 million, up 17% year-over-year, while total revenue was $40.9 million, up 13% year-over-year [5][26] - Adjusted EBITDA for Q3 was negative $297,000, representing an adjusted EBITDA margin of negative 1%, which is a $4.2 million improvement over Q3 of 2024 [5][29] - The company ended Q3 with $113.5 million in cash and short-term investments and no debt [5][29] Business Line Data and Key Metrics Changes - Revenue growth was driven by both large and small matters, particularly in multi-terabyte matters [26][27] - Services revenues, including Disco Managed Review and Professional Services, were $5.7 million [27] Market Data and Key Metrics Changes - The number of customers contributing over $100,000 in total revenue over the last 12 months reached 326, accounting for 76% of total revenue [6] - The adoption of Cecilia AI more than tripled year-over-year, with consistent growth in auto-review adoption throughout 2025 [7][20] Company Strategy and Development Direction - The company is focusing on large multi-terabyte matters and has refined its approach to target customers that best fit its capabilities [9][10] - Disco has initiated a marketing and sales effort specifically targeting intellectual property litigation, highlighting its strengths in this area [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth acceleration and operational execution, emphasizing the importance of delivering value to customers [5][6] - The company is positioned to be a disruptor in the legal technology industry, leveraging its core platform and AI capabilities [12][25] Other Important Information - The company recognized $1.3 million in revenue from a contingent case, which was a significant contributor to the quarter's results [26][36] - The gross margin in Q3 was 77%, compared to 74% in the prior year [27] Q&A Session Summary Question: About the contingent liability or the contingent case - Management indicated that there are a small number of other contingent cases in the system, but nothing close to the size of the one recognized in Q3 [35][36] Question: Regarding the target for in-quarter EBITDA break-even for Q4 of 2026 - Management confirmed that the target for adjusted EBITDA break-even remains Q4 of 2026, while acknowledging the potential for earlier profitability [38]

Revenue Performance - Revenue for the three months ended September 30, 2025, was $40.9 million, representing a 13% increase from $36.3 million in the same period of 2024[140]. - For the nine months ended September 30, 2025, revenue was $115.7 million, a 7% increase from $107.8 million in the same period of 2024[140]. - Total revenue increased by $4.7 million, or 13%, for the three months ended September 30, 2025, compared to the same period in 2024[170]. - Total revenue increased by $7.8 million, or 7%, for the nine months ended September 30, 2025, compared to the same period in 2024[176]. - Revenue from new customers added since September 30, 2024 contributed $4.7 million, while revenue from existing customers decreased by $1.4 million[170]. - Revenue generated from software product offerings increased by $5.1 million, or 17%, for the three months ended September 30, 2025[171]. - Revenue from software product offerings increased by $9.5 million, or 11%, for the nine months ended September 30, 2025[177]. - Subscription revenue represented 9% of total revenue for the three months ended September 30, 2025, compared to 11% in the same period of 2024[157]. - Usage-based revenue accounted for 91% of total revenue for the three months ended September 30, 2025, up from 89% in the same period of 2024[157]. Expenses and Losses - The net loss for the three months ended September 30, 2025, was $13.7 million, compared to a net loss of $9.2 million in the same period of 2024[140]. - Adjusted EBITDA for the three months ended September 30, 2025, was $(0.3) million, an improvement from $(4.5) million in the same period of 2024[141]. - Total cost of revenue increased by $0.3 million, or 3%, for the three months ended September 30, 2025, primarily due to a $0.6 million increase in cloud hosting costs[172]. - Research and development expenses increased by $0.7 million, or 5%, for the three months ended September 30, 2025, driven by a $1.1 million increase in personnel costs[173]. - General and administrative expenses increased by $7.3 million, or 75%, for the three months ended September 30, 2025, primarily due to a $6.9 million increase in professional services costs[175]. - Total cost of revenue increased by $1.3 million, or 5%, for the nine months ended September 30, 2025, primarily due to a $1.6 million increase in cloud hosting costs[178]. - Research and development expenses increased by $3.9 million, or 10%, for the nine months ended September 30, 2025, driven by a $4.5 million increase in personnel costs[179]. - Sales and marketing expenses decreased by $1.5 million, or 3%, for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to a decrease in personnel costs and marketing expenses[180]. - General and administrative expenses increased by $7.4 million, or 23%, for the nine months ended September 30, 2025, mainly due to a rise in professional services costs related to legal fees[181]. - Adjusted EBITDA for the nine months ended September 30, 2025, was $(8.1) million, an improvement from $(14.4) million in the same period of 2024[186]. Cash and Financing - The company had $28.8 million in cash and cash equivalents and $84.7 million in short-term investments as of September 30, 2025[140]. - Cash used in operating activities for the nine months ended September 30, 2025, was $15.7 million, an increase of 45% from $10.8 million in the same period of 2024[193]. - Net cash used in investing activities decreased by $43.8 million to $8.3 million for the nine months ended September 30, 2025, compared to $52.2 million in 2024[197]. - Cash provided by financing activities was $0.1 million for the nine months ended September 30, 2025, a decrease of $20.1 million from cash used in financing activities of $20.0 million in 2024[198]. - As of September 30, 2025, the company had cash and cash equivalents of $28.8 million and short-term investments totaling $84.7 million[187]. - Total future cash requirements as of September 30, 2025, are estimated at $93.1 million, including operating lease commitments and cloud platform purchase commitments[189]. - The company expects to meet its longer-term cash requirements primarily from cash flow from operating activities and available cash and cash equivalents[188]. - The company may seek additional equity or debt financing in the future to support operations and innovation[192]. Strategic Initiatives - The company plans to expand its international customer base, particularly in the United Kingdom and India, where less than 10% of revenue was generated from customers outside the United States[154]. - The company intends to continue pursuing strategic acquisitions to enhance its product offerings and market presence[155]. - The launch of the ediscovery chatbot, Cecilia, is expected to enhance lawyer productivity and was released in Q4 2023 in the U.S. and Q3 2024 in Europe[146]. Accounting and Compliance - The company allocates purchase consideration for acquisitions to tangible assets, liabilities, and intangible assets based on estimated fair values, with excess recorded as goodwill[203]. - Significant estimates in valuing intangible assets include future expected cash flows from acquired users and technology, useful lives, and discount rates[203]. - The company is classified as an emerging growth company under the JOBS Act, allowing it to take advantage of certain reporting exemptions[205]. - The company has opted not to use the extended transition period for complying with new or revised financial accounting standards, adopting them simultaneously with other public companies[205]. - As a smaller reporting company, the company is not required to provide quantitative and qualitative disclosures about market risk[206].

INVESTOR PRESENTATION Q3 FY25 Disclaimer Forward-Looking Statements The forward-looking statements contained in this presentation are also subject to additional risks, uncertainties, and factors, including those more fully described in our filings with the Securities and Exchange Commission ("SEC"), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. Further information on potential risks that could affect actual results will be included in the subsequent periodic and curre ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of CarMax, Inc. investors for securities purchased between June 20, 2025, and September 24, 2025, due to alleged misleading statements regarding the company's growth prospects [1][5]. Group 1: Lawsuit Details - The lawsuit claims that CarMax's defendants overstated the company's growth prospects, attributing earlier growth in the 2026 fiscal year to temporary factors related to customer behavior influenced by tariff speculation [5]. - Investors are encouraged to join the class action, with the deadline to serve as lead plaintiff set for January 2, 2026 [1][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving notable recoveries, including over $438 million in 2019 [4].

DISCO Announces Third Quarter 2025 Financial Results Total Revenue of $40.9 Million, A Year over Year Increase of 13% AUSTIN, Texas - November 5, 2025 - CS Disco, Inc. ("DISCO") (NYSE: LAW) today announced financial results for its third quarter ended September 30, 2025. "Our strategy to bring large clients and large matters to DISCO continued to gain traction in the third quarter with meaningful acceleration in both software and total revenue," said Eric Friedrichsen, CEO of DISCO. "The growing number of l ...

Core Insights - CS Disco Inc (LAW) is expected to report a quarterly earnings per share (EPS) of -$0.06 and revenue of approximately $38.5 million on November 5, 2025 [1][5] - The company has a negative price-to-earnings (P/E) ratio of -6.47, indicating ongoing challenges with profitability [1] Financial Metrics - Despite negative earnings, LAW's price-to-sales ratio stands at 2.49, suggesting that investors are willing to pay $2.49 for every dollar of sales, reflecting some investor confidence [2][5] - The enterprise value to sales ratio is slightly lower at 2.40, closely aligning with the price-to-sales ratio [2] - The company maintains a low debt-to-equity ratio of 0.06, indicating a conservative approach to debt usage [3][5] - LAW's current ratio is strong at 6.75, suggesting it is well-positioned to cover short-term liabilities with short-term assets [3][5] Cash Flow and Profitability - The enterprise value to operating cash flow ratio is -22.95, indicating negative operating cash flow, which may raise concerns for investors [4] - The earnings yield is reported at -15.46%, further highlighting the company's profitability challenges [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in previous years [4].

Core Points - Rosen Law Firm is reminding purchasers of Marex Group plc securities from May 16, 2024, to August 5, 2025, about the December 8, 2025, lead plaintiff deadline [1] - Investors who purchased Marex securities during the specified period may be entitled to compensation through a contingency fee arrangement [1] Class Action Details - A class action lawsuit has been filed against Marex Group plc, with allegations of materially false and misleading statements regarding the company's financial practices [4] - Specific claims include Marex selling over-the-counter financial instruments to itself, inconsistencies in financial statements, and misleading positive statements about the company's business and prospects [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience [3] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]